Tag: GlobeNewswire

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at Chardan’s 10th Annual Healthcare Conference on October 20, 2026 at 9:30am ET.

The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Media Response:
Media@lexeotx.com

Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com

LT350 Emerges as a Nationally Recognized Solution to Datacenter Resistance

Multi-Billion-Dollar GPU Access Market Creates Major Opportunity for Auddia

Strategic Partnership Discussions Advance Across Fiber, Real Estate, and Critical Infrastructure

BOULDER, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE) — Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), an AI-first technology company pursuing a merger that, if completed, would form McCarthy Finney, an AI-native operating company, today announced that it has posted a comprehensive CEO Letter to Shareholders on its investor relations website. The letter provides an in-depth update on the Company’s progress toward the proposed merger with Thramann Holdings, highlights significant operational achievements across subsidiaries, and outlines the rapidly expanding opportunity surrounding LT350, a distributed AI-datacenter platform that would become a subsidiary of McCarthy Finney upon merger closing.

LT350: A Category-Defining AI Infrastructure Platform

In the posted letter, CEO Jeffrey J. Thramann details the emergence of LT350 as one of the most compelling solutions to the growing community resistance facing traditional datacenter development. LT350 deploys distributed, AI ready datacenters as solar canopies in the airspace above existing parking lots, integrating GPU compute, battery storage, liquid cooling, microgrid controls, fiber connectivity, and cloud orchestration.

This architecture directly addresses the land use, water consumption, noise, and permitting challenges slowing hyperscale datacenter expansion. LT350 has recently gained national media coverage, including appearances on Fox Business, Bloomberg, Cheddar, and multiple print outlets, and is in active discussions with fiber providers, REITs, convenience store chains, QSRs, logistics operators, and critical infrastructure organizations.

Strategic Partnerships and National Footprint Development

The letter highlights LT350’s strategy of forming a national consortium of real estate and fiber optic partners to present what is expected to be the largest footprint of potential distributed AI datacenter sites in the United States. This model is designed to support rapid deployment, premium pricing, and proximity driven inference capacity for hyperscalers, neoclouds, foundation model developers, and enterprise AI buyers.

LT350 also continues to advance its first pilot canopy at a hospital in the Dallas MSA.

AI Infrastructure Market: Multi-Billion-Dollar GPU Access Contracts

The CEO Letter outlines several major GPU access contracts disclosed across the industry, including:

• Akamai’s $11.6B to $20B multi-year agreement with Anthropic
• Nscale’s $3.5B contract with Figure AI for 100,000 GPUs
• Nebius’s pricing guidance for GPU compute contracts of $12M/MW in early 2026, $20M/MW in mid-year, and → $30M+ per MW being discussed in future contracts
• Applied Digital’s $5.2B multi-year hosting agreement

These transactions demonstrate the scale of long duration commitments GPU access customers are making to secure future compute capacity. The Company believes LT350 is optimally positioned to compete for premium, proximity driven inference contracts due to its distributed architecture, patented canopy design, and capital efficient cost structure.

LT350’s Cost Advantage and Deployment Speed

The letter also highlights recent CRE industry data showing AI ready datacenter construction costs ranging from $15–$35 million per MW, with some markets exceeding $40 million per MW. LT350’s patented canopy architecture is expected to deliver comparable AI ready infrastructure at approximately $3 million per MW, with significantly shorter deployment timelines and reduced onsite labor due to prefabricated cartridges.

Next Steps

Auddia expects to provide additional updates on LT350’s strategic progress, announce new partnerships as agreements are executed, and continue working toward completion of the proposed merger. The Company remains focused on positioning the combined entity for long term value creation.

The full CEO Letter to Shareholders is available now on Auddia’s investor relations website.

About the Merger to form McCarthy Finney (MCFN)

Auddia entered into a definitive merger agreement with Thramann Holdings, LLC on February 17, 2026. If completed, the transaction would combine Auddia with three early-stage, AI-native operating companies wholly owned by Thramann Holdings: LT350, Influence Healthcare, and Voyex. The combined company would be renamed McCarthy Finney Inc. and is expected to trade under the ticker MCFN, subject to applicable approvals and listing requirements. McCarthy Finney would operate as an AI holding company supporting LT350, Influence Healthcare, Voyex, and Auddia with AI and Web3 capabilities.

• LT350 is a distributed AI datacenter company with 14 issued patents and 3 pending patent applications covering its proprietary solar parking lot canopy infrastructure platform. The platform integrates modular battery storage and GPU cartridges into the canopy ceiling to convert the airspace of underutilized parking areas into distributed AI datacenters. LT350 aims to build a secure, low latency, cost effective, and rapidly deployable edge network while supporting local power infrastructure resilience.
• Influence Healthcare is a healthtech company leveraging AI, blockchain, and vertical integration to empower surgeons to drive adoption of value based care (VBC) to the surgical specialties. The Company’s mission is to leverage technology and value based enterprises (VBEs) to build an alternative healthcare system that minimizes the corporate practice of medicine, eliminates administrative waste, and enhances the autonomy and pay of health care providers to empower them to improve quality and return the patient physician relationship to the center of medicine.
• Voyex is a travel services platform that leverages agentic AI, an integrated fintech platform, and utilization of charter and private jet aircraft to significantly improve the travel experience. The Company aims to alleviate the leading pain points for travelers of lengthy flight delays and cancellations.

About Auddia Inc.

Auddia, through its proprietary AI platform for audio identification and classification, is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. Auddia’s Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Auddia’s flagship audio superapp, called faidr, delivers multiple industry firsts, including:

• Ad-free listening on any AM/FM radio station
• Content skipping across any AM/FM station
• One-touch skipping of entire podcast ad breaks
• Integrated artist discovery experiences

For more information, visit www.auddia.com.

Cautionary Note on Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995, concerning Auddia, Thramann Holdings, and the proposed merger between Auddia and Thramann Holdings (the “Proposed Transaction”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Auddia’s and Thramann Holdings’ management expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the structure, timing and completion of the proposed merger by and between Auddia and Thramann Holdings, and the expected effects, perceived benefits or opportunities of the Proposed Transaction; the combined company’s listing on Nasdaq after the closing of the Proposed Transaction; expectations regarding the structure, timing and completion of the financing needed to close the Proposed Transaction, including investment amounts from investors, timing of closing of the Proposed Transaction, expected proceed, expectations regarding the use of proceeds, and impact on ownership structure; the anticipated timing of the closing; the expected executive officers and directors of the combined company; each company’s and the combined company’s expected cash position at the closing and cash runway of the combined company following the proposed merger and any additional financing; the future operations of the combined company, including research and development activities; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any products and services of the combined company; the cash balance of the combined entity at closing; expectations related to the anticipated timing of the closing of the Proposed Transaction (the “Closing”); the expectations regarding the ownership structure of the combined company; the expected trading of the combined company’s stock on Nasdaq under the ticker symbol “MCFN” after the Closing; and other statements that are not historical fact.

All statements other than statements of historical fact contained in this communication are forward-looking statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are made based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, concerning future developments and their potential effects. There can be no assurance that future developments affecting Auddia, Thramann Holdings, or the Proposed Transaction will be those that have been anticipated.

These forward-looking statements involve a number of risks and uncertainties, some of which are beyond Auddia’s or Thramann Holdings’ control, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the conditions to the Closing or consummation of the Proposed Transaction are not satisfied, including the failure to timely obtain approval of the proposed merger from Auddia’s stockholders the risk that the required financing is not obtained in a timely manner, if at all; uncertainties as to the timing of the consummation of the Proposed Transaction; risks related to Auddia’s continued listing on Nasdaq until closing of the Proposed Transaction and the combined company’s ability to remain listed following the Closing; uncertainties regarding the impact any delay in the Closing would have on the anticipated cash resources of the combined company, and other events and unanticipated spending and costs that could reduce the combined company’s cash resources; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; the effect of the announcement or pendency of the merger on Auddia’s or Thramann Holdings’ business relationships, operating results and business generally; costs related to the merger; the risk that as a result of adjustments to the exchange ratio, Auddia’s or Thramann Holdings’ stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of Auddia’s common stock relative to the value suggested by the exchange ratio; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance the development of its products and services; costs of the Proposed Transaction and unexpected costs, charges or expenses resulting from the Proposed Transaction; potential adverse reactions or changes to business relationships, operating results, and business generally, resulting from the announcement or completion of the Proposed Transaction.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in Auddia’s Annual Report on Form 10-K for the year ended December 31, 2025, which was originally filed with the SEC on March 6, 2026, subsequent Quarterly Reports on Form 10-Q filed with the SEC, and in other filings that Auddia makes and will make with the SEC in connection with the Proposed Transaction, including the Form S-4 and Proxy Statement described below, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Auddia from time to time. Should one or more of these risks or uncertainties materialize, or should any of Auddia’s or Thramann Holdings’ assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither Auddia nor Thramann Holdings undertakes or accepts any duty to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Auddia or Thramann Holdings.

No Offer or Solicitation

This communication and the information contained herein is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.

Important Additional Information about the Proposed Transaction Will be Filed with the SEC

This communication relates to the proposed merger involving Auddia and Thramann Holdings and may be deemed to be solicitation material in respect of the proposed merger. In connection with the proposed Transaction, Auddia intends to file relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that will contain a proxy statement (the “Proxy Statement”) and prospectus. This communication is not a substitute for the Form S-4, the Proxy Statement or for any other document that Auddia may file with the SEC and/or send to Auddia’s stockholders in connection with the proposed merger. AUDDIA URGES, BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AUDDIA, THRAMANN HOLDINGS, THE PROPOSED TRANSACTION AND RELATED MATTERS.

Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by Auddia with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed by Auddia with the SEC will also be available free of charge on Auddia’s website at www.auddia.com or by contacting Auddia Investor Relations at investors.auddiainc.com/contact. In addition, investors and stockholders should note that Auddia communicates with investors and the public through its investor-relations website at investors.auddiainc.com.

Participants in the Solicitation

Auddia, Thramann Holdings, and their respective directors and certain of their executive officers and other members of management may be deemed to be participants in the solicitation of proxies from Auddia’s stockholders in connection with the proposed transaction under the rules of the SEC. Information about Auddia’s directors and executive officers, including a description of their interests in Auddia, is included in Auddia’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 6, 2026. Additional information regarding the persons who may be deemed participants in the proxy solicitations, including about the directors and executive officers of Thramann Holdings, and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the sources indicated above.

Investor Relations

Kirin Smith, President
PCG Advisory, Inc.
ksmith@pcgadvisory.com
www.pcgadvisory.com

• New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment pace
• Initial readout timing to be updated by year-end based on demonstrated Q4 enrollment increases
• Overall trial duration remains on track

BROOMFIELD, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced an update to the enrollment criteria and expected timing of the initial readout from its pivotal CLARITY clinical trial. Based on current enrollment levels and the required three-month postoperative follow-up period, Aclarion will provide an update on enrollment levels and anticipated timeline for the initial readout by year-end.

The Company emphasizes that this timing update does not change the overall expected duration of the CLARITY trial at this time.

Enrollment and Inclusion/Exclusion Criteria

CLARITY was intentionally designed with highly optimized inclusion and exclusion criteria to remove confounding factors that have historically complicated chronic low back pain studies. These criteria strengthened the scientific rigor of the trial but significantly narrowed the pool of eligible patients at participating sites.

Over the past nine months, Aclarion implemented multiple operational measures to accelerate enrollment without altering the criteria, including:

• Increasing site level engagement and training
• Enhancing patient identification workflows
• Adding dedicated internal study coordination resources
• Expanding outreach to referring physicians
• Improving communication pathways between radiology and surgical teams

Despite these efforts, enrollment did not increase at the pace required to support a Q4 2026 initial readout.

Revised Criteria to Reflect Real World Chronic Low Back Pain

Recognizing that the optimized criteria were excluding a substantial portion of real world chronic low back pain patients, Aclarion undertook a comprehensive review of the inclusion/exclusion framework in partnership with the primary investigator and lead surgeon researchers at each enrollment site. The Company subsequently implemented revised criteria that:

• Maintain scientific rigor
• Better reflect the clinical reality of chronic low back pain
• Expand the pool of eligible patients
• Improve alignment with how Nociscan is used in everyday practice

These revised criteria have now been fully approved by the Institutional Review Boards (IRBs) at 9 of 11 active CLARITY sites, with the other 2 active sites using revised criteria for screening prior to local IRB approval. The revised criteria will be used at all newly added sites, including NYU and the most recent center activated for enrollment.

Overall Length of the CLARITY Trial Remains on Track

The IRB approval process temporarily slowed enrollment as sites paused screening under the prior criteria. With approvals now complete, Aclarion expects meaningful acceleration in enrollment going forward.

Importantly, the Company does not anticipate that this adjustment will extend the overall length of the CLARITY trial. The revised criteria are expected to:

• Increase the number of eligible patients
• Improve enrollment consistency across sites
• Enhance the representativeness of the study population
• Strengthen the real-world applicability of the eventual study results

With the pace of enrollment expected to increase under the revised criteria, Aclarion believes the trial remains on track to complete within its originally anticipated timeline.

Brent Ness, Aclarion CEO said, “CLARITY is designed to deliver the highest level of scientific rigor, and that required us to begin the study with very narrow inclusion criteria. As we gained real-world insight into patient flow across our sites, we needed to adjust those criteria to better reflect the chronic low back pain population surgeons actually treat. With IRB approvals now complete at nearly all active sites, we expect enrollment to accelerate meaningfully. We remain focused on enrollment and look forward to providing an update by year end with timing for the initial readout. Importantly, our confidence in the overall timeline remains on track with the importance of CLARITY demonstrating Nociscan’s clinical value.”

Chronic low back pain is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.

For more information about CLARITY, please visit: CLARITY Trial

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: info@aclarion.com

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.  For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding that we will provide an update on enrollment levels and anticipated timeline for the initial readout by year-end, the expectation that we will significantly accelerate enrollment of patients in our ongoing clinical trial, that the overall duration of the CLARITY Trial Remains on Track and that the Company does not anticipate that this initial readout adjustment will extend the overall length of the CLARITY trial, that the revised criteria are expected to: increase the number of eligible patients; improve enrollment consistency across sites; enhance the representativeness of the study population and; strengthen the real-world applicability of the eventual study results; with the pace of enrollment expected to increase under the revised criteria, and, the continued expansion of the CLARITY trial to generate the high-quality evidence needed to advance Nociscan. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Media Contacts:

Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com

Available for purchase on the Company’s website, the new direct-to-consumer sales channel expands nationwide access and marks a pivotal step towards commercialization 

With a growing number of consumers registering on the website ahead of launch, customers can now purchase The Home Defense™ directly HERE

Las Vegas, NV, Oct. 08, 2026 (GLOBE NEWSWIRE) — Alternative Ballistics Corporation (OTCQB: ALBC) (“ALBC” or the “Company”), a public safety technology company focused on next-generation less-lethal solutions, has launched a direct-to-consumer ecommerce platform that allows eligible customers to purchase The Home Defense^™ directly from the Company’s website at https://alternativeballistics.com/product/the-home-defense/.

The Home Defense™ was developed to provide responsible firearm owners with a less-lethal-first option that may allow them to attempt to stop or deter a threat before resorting to lethal force, when appropriate under the circumstances. The ecommerce platform represents an important component of the Company’s commercialization strategy by expanding customer access while creating a scalable, direct sales channel.

“Launching direct-to-consumer sales is an important step in making The Home Defense^™ broadly available to consumers,” said Jason LeBlanc, Chief Operating Officer of Alternative Ballistics. “Consumers have been asking when they could purchase directly from Alternative Ballistics, and we’re pleased to now provide them with a convenient online platform where customers can learn more about the product, access educational resources, and place orders from anywhere we are authorized to sell.”

“The launch of our direct-to-consumer platform is a pivotal step in executing our commercialization strategy and establishing a scalable sales channel for The Home Defense^™,” said Steve Luna, Chief Executive Officer of Alternative Ballistics. “Selling directly to consumers enables us to build direct relationships with end users, strengthen our brand, and broaden national awareness of the product as we work to create long-term value for our shareholders.”

The Company believes many homeowners are seeking additional self-defense options that provide greater flexibility during high-stress encounters. By offering a less-lethal-first capability, The Home Defense^™ may provide users with added peace of mind while helping preserve the option to transition to conventional ammunition if circumstances require. In certain situations, a less-lethal alternative may help reduce the risk of serious injury and lessen the legal, financial, and emotional consequences associated with the use of deadly force. Defensive encounters are highly fact-specific, and users remain responsible for complying with all applicable laws and exercising sound judgment.

The new ecommerce platform will serve as a central resource where consumers can access product information, instructional materials, frequently asked questions, and future product updates. The Company expects the ecommerce launch to complement its expanding dealer network while increasing consumer awareness and accelerating adoption of The Home Defense^™ nationwide.

About Alternative Ballistics Corporation

Alternative Ballistics Corporation is a public safety technology company focused on developing patented, less-lethal solutions designed to preserve life, reduce risk, and protect individuals in high-stress situations. The Alternative^® is a patented system intended to bridge the capability gap between traditional less-lethal tools and lethal force by providing a controlled force option designed to de-escalate critical incidents. The Company plans to introduce a consumer-focused version of its technology to the U.S. commercial market under The Home Defense^™ brand. This consumer product is intended to provide individuals with an additional, less-lethal self-defense option designed to establish intent, reduce potential liability, and help mitigate the risk of severe or fatal outcomes prior to the use of lethal force.

Cautionary Note Regarding Forward Looking Statements

This news release and statements of ALBC’s management in connection with this news release or related events contain or may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would”, “optimistic” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control and that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: the Company’s ability to convert pipeline opportunities into sales; changes in regulatory requirements affecting the Company’s products; international political, economic, and regulatory conditions; the Company’s ability to secure necessary product approvals in foreign jurisdictions; competition in the less-lethal technology market; and the Company’s ability to successfully launch The Home Defense™ product. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review ALBC’s filings with the U.S. Securities and Exchange Commission for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law. 

Company Contact:

info@alternativeballistics.com
www.alternativeballistics.com

Investor Relations Contact:

Adam S. Holdsworth
MZ Group – MZ North America
305-341-9451
ALBC@mzgroup.us
www.mzgroup.us

Herzliya, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) — Beamr Imaging Ltd. (NASDAQ: BMR), a leader in video optimization technology and solutions, today announced the Company will present at the following investor conference:

Event:	The ThinkEquity Conference
Date:	October 15, 2026
Time:	10:00-10:30 AM
Location:	Mandarin Oriental, New York
Presenters:	Sharon Carmel, Founder and Chief Executive Officer
	Danny Sandler, Chief Financial Officer

Beamr’s management team will also meet with select investors in one-on-one meetings during the conference.

“Over the past year, we have advanced from technology validation towards commercialization in the autonomous vehicle (AV) market. We laid out our strategic plan and have been executing it step by step, reporting milestones along the way,” said Sharon Carmel, Beamr CEO. “Through our availability in Intempora’s RTMaps AI Store, we are bringing our technology into the workflows AV teams already use, enabling video data reduction across logging, cloud processing, simulation and training.”

Carmel added: “Our focus now is helping AV teams evaluate compression on their own data and models, and translating that progress into adoption and long-term customer relationships. Across our broader business, we have joined the VAST Cosmos Partner Program and secured a three-year license renewal with a major global streaming platform. As announced on September 30, we expect fiscal year 2026 revenues to grow by approximately 50% over fiscal year 2025, based on our current expectations regarding existing customer agreements, renewals and broader business activities.”

Learn more in Beamr Investors website: https://www.investors.beamr.com/

The revenue guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the “Forward-Looking Statements” safe harbor section below for information on the factors that could cause the Company’s actual results to differ materially from these forward-looking statements, as well as the Company’s Annual Report on 20-F for the fiscal year ended December 31, 2025, including in “Operating and Financial Review and Prospects” and “Risk Factors”, for further context.

About Beamr

Beamr (Nasdaq: BMR) is a world leader in content-adaptive video compression, trusted by top media companies including Netflix and Paramount. Beamr’s perceptual optimization technology (CABR) is backed by 53 patents and a winner of Emmy® Award for Technology and Engineering. The innovative technology reduces video file sizes by up to 50% while preserving quality and enabling AI-powered enhancements.

Beamr powers efficient video workflows across high-growth markets, such as media and entertainment, user-generated content, machine learning, and autonomous vehicles. Its flexible deployment options include on-premises, private or public cloud, with convenient availability for Amazon Web Services (AWS) and Oracle Cloud Infrastructure (OCI) customers.

For more details, please visit www.beamr.com or the investors’ website www.investors.beamr.com and follow us on Linkedin and X.

Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements in this communication may include, among other things, statements about Beamr’s strategic and business plans, technology, relationships, objectives and expectations for its business, the impact of trends on and interest in its business, intellectual property or product and its future results, operations and financial performance and condition, including statements relating to the Company’s anticipated revenues and other results for the full year 2026, its autonomous vehicle market strategy and commercialization efforts, the potential adoption of its technology by autonomous vehicle customers, opportunities arising from its availability through Intempora’s RTMaps AI Store and the development of customer relationships, participation in industry partnerships. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on February 26, 2026 and in subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of the date hereof and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:
investorrelations@beamr.com

ENGLEWOOD CLIFFS, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) — ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today announced that it plans to release results for the third quarter ended September 30, 2026, before the market opens on Thursday, October 22, 2026. Management will also host a conference call and audio webcast at 10:00 a.m. ET on October 22, 2026, to review the Company’s financial performance and operating results.

Chairman and Chief Executive Officer Frank Sorrentino III and Senior Executive Vice President and Chief Financial Officer William S. Burns will host the call. The conference call dial-in number is 1 (585) 542-9983, meeting ID: 828 757 770. Please dial in at least five minutes before the start of the call to register. An audio webcast of the conference call will be available to the public, on a listen-only basis, via the “Investor Relations” link on the Company’s website https://www.ConnectOneBank.com or at http://ir.connectonebank.com.

An online archive of the webcast will be available following the completion of the conference call at https://www.ConnectOneBank.com or at http://ir.connectonebank.com.

About ConnectOne Bancorp, Inc.
ConnectOne Bancorp, Inc., is a modern financial services company that operates, through its subsidiary, ConnectOne Bank, and the Bank’s fintech subsidiary, BoeFly, Inc. ConnectOne Bank is a high-performing commercial bank offering a full suite of banking & lending products and services that focus on small to middle-market businesses. BoeFly, Inc. is a fintech marketplace that connects borrowers in the franchise space with funding solutions through a network of partner banks. ConnectOne Bancorp, Inc. is traded on the Nasdaq Global Market under the trading symbol “CNOB,” and information about ConnectOne may be found at https://www.connectonebank.com.

Investor Contact:

William S. Burns
Senior Executive VP & CFO
201.816.4474; bill.burns@cnob.com

Media Contact:

Shannan Weeks
MikeWorldWide
732.299.7890; sweeks@mww.com

Baltimore, MD, Oct. 08, 2026 (GLOBE NEWSWIRE) — Weight regain after initial weight loss is a recognized pattern among individuals pursuing lasting metabolic change. Trilivy™, a science-backed, coach-guided metabolic health system, points to lean mass preservation and continued support as the two factors that keep metabolic health and its results in place. 

“Body composition is the more meaningful measure of metabolic progress, specifically what happens to visceral fat and lean mass during the weight loss phase. Tracking both together shows whether baseline energy use has actually improved and can be used to support metabolic health after the program ends,” said Satya Jonnalagadda, PhD, MBA, RD, Vice President, Scientific & Clinical Affairs at Trilivy, who leads the company’s scientific and clinical research strategy.

Lean Mass Keeps the Metabolism Working

Rapid weight loss can draw from lean mass, including muscle, a metabolically active tissue that plays a direct role in how efficiently the body burns energy. Losing it can slow the metabolism and make results harder to sustain. This places body composition at the center of long-term success. 

Visceral Fat Reduction Is An Important Body Composition Marker for Lasting Weight Management

Visceral fat, the tissue surrounding the organs that releases inflammatory molecules and hormones affecting insulin sensitivity and cardiovascular risk, is also the fat most likely to return first once a structured program ends. 

A Behavior Framework Built for the Years After the First 12 Weeks

Lasting metabolic change depends on habit formation that extends beyond the active phase of any program. A behavioral framework built around repeatable micro-habits gives individuals a way to sustain progress once daily structure and accountability are no longer built into a formal plan.

Human Coaching Is the Behavioral Layer That Holds Results in Place

Human support provides accountability and real-time course correction through the weight loss phase and beyond, addressing the adherence patterns that often determine whether early progress becomes a lasting outcome.

How Trilivy’s Reset, Refine, and Renew System Can Help Support Long-Term Metabolic Health

Trilivy pairs structured nutrition from its Trilivy Fuelings and Lean & Green™ meals with a network of independent Trilivy coaches and the Habits of Health® Transformational System. Trilivy’s three-phase system includes Reset, which works to reset the body’s metabolism and reverse metabolic dysfunction; Refine, which focuses on optimizing metabolic flexibility and body composition; and Renew, which supports long-term metabolic health, vitality and healthspan, designed to carry past the initial phase of a program and into the years that follow. About 90% of Trilivy’s independent coaches started as clients, bringing direct personal experience to the support relationship.

Key Facts:

• 98% of lean mass was retained by individuals on the Reset 5 & 1 Plan at 16 weeks, and 97% on the Reset 4 & 2 Active Plan*
• 14% reduction in visceral fat at 16 weeks on the Reset 5 & 1 Plan*
• More than 90% of U.S. adults are metabolically unhealthy¹
• Participants on the Reset 5 & 1 Plan working with a coach lost up to 10 times more weight and 17 times more fat than those on a self-directed approach*

FAQs

Question: Will I gain the weight back after a structured program?
Answer: Metabolic outcomes that last depend on what happens to your metabolism during a program. Preserving lean mass keeps the metabolism active, and building habits keeps it supported. Individual results vary.

Question: Does losing muscle slow your metabolism?
Answer: It can. Muscle is metabolically active tissue, so losing it during weight loss can slow the metabolism and make it harder to maintain results.

Question: How do I keep my results for the long term?
Answer: Lasting results come from ongoing metabolic health, not a short-term push toward a goal. Structured habit formation paired with coach accountability helps translate a program’s early progress into changes that hold up beyond the initial phase. 

Question: Does coaching actually help your results last?
Answer: Yes. Coaching focuses on accountability and the habits that protect metabolic health over time.

* Trilivy™ recommends that you contact your healthcare provider before starting and throughout your weight loss journey.

* Arterburn LM, et al. Randomized controlled trial assessing two commercial weight loss programs in adults with overweight or obesity. Obesity Science & Practice. 2019. https://onlinelibrary.wiley.com/doi/10.1002/osp4.312. In a clinical study, individuals on the Reset 5 & 1 Plan experienced a reduction of 14% visceral fat and 98% of lean mass was retained at 16 weeks. Those on the Reset 5 & 1 Plan with the support of a coach lost up to 10x more weight and 17x more fat than those who tried to lose weight on their own.

¹ O’Hearn M, et al. Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018. Journal of the American College of Cardiology. 2022;80(2):138-151. doi:10.1016/j.jacc.2022.04.046.

About Medifast and Trilivy

Medifast (NYSE: MED) is the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy. Designed to address the challenges of metabolic dysfunction, the company’s holistic approach integrates science-backed plans and products, personal 1:1 coaching, a supportive community, and behavioral science support to develop healthy habits.
Driven to improve metabolic health through advanced science and comprehensive behavioral support, Medifast has introduced Metabolic Synchronization®, a breakthrough science that targets metabolic dysfunction through a comprehensive system focused on fat loss, lean mass preservation, and long-term health. Trilivy’s comprehensive three-phase metabolic health system is designed to help people reset their metabolism, refine their health, and renew their lives. By integrating science, coaching, and healthy habits into a single approach, Trilivy helps people look, feel, and live better.
Backed by more than 45 years of clinical heritage, Medifast continues to advance its mission of lifelong transformation through metabolic science and human connection™. For more information, visit trilivyhealth.com and medifastinc.com.

CONTACT: Sarah Evans, CEO
Zen Media
sarah@zenmedia.com

CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) — Akamai Technologies, Inc. (Nasdaq: AKAM), today announced that the company will hold a conference call for investors on Thursday, November 5, 2026, at 4:30 p.m. ET. The call will include the company’s third quarter 2026 financial results and may include forward-looking financial guidance from management. The call will also be broadcast live via the internet at Akamai’s Investor Relations page.

The live dial-in information for the conference call is:

• U.S. only: (833) 634-5020
• International: (412) 902-4238
• Password: Akamai Technologies call

In addition, a replay of the call will be available for two weeks following the conference by calling (855) 669-9658 (or (412) 317-0088 for international calls) and using Conference ID: 9787784. The archived webcast of this event may be accessed through the Akamai website.

About Akamai
Akamai is the cloud company that powers and protects an AI-driven world. Our cloud platform extends high-performance cloud computing from the core to the edge, enabling organizations to build and scale next-generation AI applications while delivering comprehensive, multilayered security to safeguard enterprises against evolving cyberthreats. Learn more at akamai.com and akamai.com/blog, or follow Akamai Technologies on X and LinkedIn.

Contacts:                       Akamai PR AkamaiPR@akamai.com

Investor Relations Invrel@akamai.com

GREENWICH, Conn., Oct. 08, 2026 (GLOBE NEWSWIRE) —  GXO Logistics, Inc. (NYSE: GXO) will hold its third quarter 2026 earnings conference call and webcast on Wednesday, November 4, 2026, at 8:30 a.m. Eastern Time. The company’s results will be released after market close on Tuesday, November 3, 2026, and made available at that time on investors.gxo.com.

Access information:
Call toll-free from U.S./Canada: 877-407-8029
International callers: +1 201-689-8029
Conference ID: 13762379
Live webcast: investors.gxo.com

A replay of the conference call will be available for approximately two weeks, until November 19, 2026, by calling toll-free (from U.S./Canada) 877-660-6853; international callers dial +1 201‑612‑7415. Use the passcode 13762379.

About GXO

GXO Logistics, Inc. (NYSE: GXO) is the world’s largest pure-play contract logistics provider and is positioned to capitalize on the rapid growth of ecommerce, automation and outsourcing. GXO has more than 150,000 team members across more than 1,000 facilities totaling more than 200 million square feet. The company serves the world’s leading blue-chip companies to solve complex logistics challenges with technologically advanced supply chain and ecommerce solutions, at scale and with speed. GXO corporate headquarters is in Greenwich, Connecticut. Visit  GXO.com  for more information and connect with GXO on  LinkedIn, X, Facebook, Instagram  and  YouTube.

Investor Contact

Kristine Kubacki, CFA
 +1 203-769-7206
kristine.kubacki@gxo.com

The new partnership between Trupanion and Cowell aims to raise awareness about growing needs within the pet community

SEATTLE, Oct. 08, 2026 (GLOBE NEWSWIRE) — Trupanion, North America’s leading pet insurer, announced today a new partnership with television personality and music executive Simon Cowell to raise awareness about the importance of protecting pets with pet insurance.

Long known for his impeccable taste and eye for quality, Cowell says he decided to work with Trupanion after thoroughly reviewing the company and taking out a policy for each of his four dogs.

“I’ve got to really trust something or love something to put my name behind it. I love animals and I love what Trupanion is doing. There’s a reason nearly 99% of their customers are happy, it’s because what they do for pets is working,” said Simon Cowell.

As part of the partnership, Trupanion and Cowell will create a series of media initiatives highlighting the importance of pet insurance and celebrating the unique bond between pets and the people who love and care for them.

“From the moment I met Simon, it was clear he takes his dogs’ care as seriously as anyone I’ve ever met. He came to us with hard questions, did his own homework, and took out a Trupanion policy for his four dogs. At Trupanion, our mission is to remove barriers to care so pets can get what they need, when they need it. Simon believes in that mission and sees the value of pet insurance and the impact Trupanion is making on pets’ lives. Together, we can help more people understand why pet insurance is so important,” said Margi Tooth, CEO and President of Trupanion.

The Growing Importance of Pet Insurance

Right now, there are more than 180 million pets across the United States and Canada. However, less than 5% of people have pet insurance. This is a growing problem because the cost of care, driven largely by advancements in veterinary medicine, means that without high-quality pet insurance, bills for unexpected accidents and illnesses can be thousands or even tens of thousands of dollars.

Meanwhile, a recent survey found that a bill of around $1,500 would force many pet parents to choose between their financial health and the health, or even life, of their pet.

“We need to start talking more about what it really costs to care for a pet over their lifetime. Veterinary care in many ways is akin to human medicine, which when used as intended, leads to pets living longer and healthier lives. But that care comes at a cost. Pet insurance is the best way to budget for those unexpected vet bills, while getting access to extraordinary veterinary care,” said Tooth.

“I love the peace of mind pet insurance brings because now you know you can afford to have your vet bills covered. And what’s especially important with Trupanion is that they can pay your vet directly, so you don’t have the stress of waiting to be paid back. How cool is that?” said Cowell.

Raising Awareness about Protecting Pets

Trupanion’s partnership with Cowell is the latest initiative by the company to raise awareness about the importance of pet insurance.

Over the last year Trupanion has launched partnerships with the Seattle Reign of the National Women’s Soccer League, the American Humane Society, the Human Animal Bond Research Institute (HABRI), and Home To Home.

To highlight Trupanion’s new partnership with Cowell, Trupanion has launched a dedicated landing spot on Trupanion.com highlighting Simon’s passion for animals, his journey with Trupanion, and how pet insurance has helped him prepare for the unexpected.

“This partnership is about bringing visibility to pet insurance as a whole. If Simon can help more pet parents understand the value of being prepared, that’s a win for the pets we all love,” said Tooth.

About Trupanion

Trupanion is a leader in medical insurance for cats and dogs throughout the United States, Canada, and certain countries in Continental Europe with over 1,000,000 pets currently enrolled. For over two decades, Trupanion has given pet owners peace of mind so they can focus on their pet’s recovery, not financial stress. Trupanion is committed to providing pet parents with the highest value in pet medical insurance with unlimited payouts for the life of their pets. With its patented process, Trupanion is the only North American provider with the technology to pay veterinarians directly in seconds at the time of checkout. Trupanion is listed on NASDAQ under the symbol “TRUP.” The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company and, in Canada, by GPIC Insurance Company or Accelerant Insurance Company of Canada. Policies are sold and administered in Canada by Canada Pet Health Insurance Services, Inc. dba Trupanion 309-1277 Lynn Valley Road, North Vancouver, BC V7J 0A2 and in the United States by Trupanion Managers USA, Inc. (in California, Trupanion Insurance Services, #0G22803, NPN 9588590). Canada Pet Health Insurance Services, Inc. is a registered damage insurance agency and claims adjuster in Quebec #603927. For more information, please visit Trupanion.com.

Corporate.Communications@trupanion.com